Overview

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2021-12-30

Target enrollment:

Participant gender:

Summary

This study aims to test the hypothesis that combining serabelisib, a PI3K alpha isoform inhibitor, with an SGLT2 inhibitor, canagliflozin will improve efficacy in the treatment of patients with advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Petra Pharma

Treatments:

Canagliflozin
Serabelisib